Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's new iteration of its guidance on meetings with sponsors reflects lessons learned during the surge in meeting requests the agency has had in the nine years since FDA issued the original formal meetings final guidance in February 2000
You may also be interested in...
Complete Submissions Are Key To Good Review Management Principles – FDA
As FDA rolls out its Good Review Management Principles - its attempt to improve FDA's timely review of drug applications through professional best practices - the agency is stressing the importance of sponsors submitting complete applications to facilitate this process
Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.